Bone Biologics Corp

BBLG Nasdaq SEC CIK 1419554
Follow Bone Biologics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$617.7K +7.4% vs same quarter last year
EPS, diluted −$0.17 +54.1% vs same quarter last year
Operating cash flow −$532.3K +10% vs same quarter last year
Operating income −$666.3K +6.8% vs same quarter last year
Net income by quarter
−$1.5M
−$1M
−$740.5K
−$666.7K
−$684.6K
−$766K
−$773.7K
−$617.7K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1B$1.5BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$3.1M
FY24-−$4.1M
FY23-−$8.9M
FY22-−$1.5M
FY21-−$1.6M
FY20$1.1B−$1.8M
FY19$1.1B−$3.4M
FY18-−$4.4M
FY17-−$7.1M
FY16$1.1B−$25.9M
FY15-−$13.9M
FY14-−$4.4M
FY13-−$1.1M
FY12-−$715.6K
FY11-−$937.6K
MarginsShare of revenue
  • Operating margin
  • Net margin
−3%−2%−1%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20−0.1%−0.2%
FY19−0.2%−0.3%
FY18--
FY17--
FY16−1.9%−2.4%
FY15--
FY14--
FY13--
FY12--
FY11--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Bone Biologics
  • Healthcare median
−100%−75%−50%−25%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBone BiologicsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20−0.2%−62.2%
FY19−0.3%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16−2.4%−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%